Prior Authorization and Coverage Contingency

Prior authorization: Not specified in the extracted policy text. Providers should verify plan-specific prior authorization requirements before scheduling distraction osteogenesis, as coverage may be contingent on meeting Aetna medical necessity criteria and plan benefits.

• Coverage is contingent on meeting the medical necessity criteria listed in this policy (see Medical Necessity section).
• When treating congenital anomalies not explicitly listed, document review by Aetna's Oral and Maxillofacial Surgery (OMS) Unit may be required.
• Check the member's benefit plan for exclusions related to dental implants or orthodontic care; DO is not covered when such procedures are excluded.

Support Indication and Coding

Documentation must support one of the listed congenital indications and include relevant clinical details, operative reports, and applicable diagnosis/procedure codes.

• Include clinical summary stating the specific congenital diagnosis (e.g., cleft lip/palate, Pruzansky Grade I/IIa hemifacial microsomia, severe mandibular deficiency >10 mm, Pierre Robin sequence with airway obstruction, syndromic/non-syndromic craniosynostosis).
• Provide objective findings demonstrating functional impairment (e.g., airway obstruction, feeding or speech impairment) and measurements supporting need for lengthening (e.g., anticipated millimeters of distraction).
• Attach relevant pre- and post-operative imaging, surgical plan (corticotomy/osteotomy details), and expected distraction protocol.
• List and bill with appropriate CPT/HCPCS/ICD-10 codes as supported by documentation (see codes section).

Consideration of Conventional Alternatives

Consideration of conventional alternatives: Providers should document why standard surgical techniques (for example, orthognathic surgery or staged grafting/osteotomy) are not expected to achieve the required functional improvement or magnitude of correction.

• Distraction osteogenesis is generally indicated when the deformity magnitude (e.g., mandibular lengthening >10 mm) or anatomy makes conventional orthognathic approaches inadequate.
• For hemifacial microsomia, indicate Pruzansky grade and why distraction is preferred over single-stage correction or grafting.
• When other congenital anomalies are treated, document OMS Unit review and rationale that DO can uniquely produce improvement unavailable with standard techniques.

Experimental/Investigational and Cosmetic Exclusions (Denial Risk)

Experimental, cosmetic, and excluded uses: The policy lists specific scenarios that are not covered or considered experimental; documenting attempts at alternatives will not make these indications payable.

• Distraction osteogenesis for acquired craniofacial defects (e.g., post-tumor resection), obstructive sleep apnea, and other non-congenital craniofacial indications is considered experimental/investigational and not covered.
• Use of bone morphogenetic proteins (BMPs), local bone marrow aspirate, or platelet gel at the osteotomy site during DO is experimental/investigational.
• DO performed solely for cosmetic improvement is excluded from coverage and may be denied.
• Ensure benefit plan exclusions for dental implants or orthodontic care are checked, as DO is not covered under plans that exclude those services.